Diaceutics stock price target lowered to 185p by RBC on FX headwinds Investing.com - RBC has reduced its price target for Diaceutics PLC (LON:DXRX) from 195p to 185p, citing unfavorable foreign exchange movements that impacted revenue estimates by 4-5%, while maintaining an Outperform rating on the stock. Despite the price target reduction, RBC notes that its new target still implies over 50% upside potential from current levels, with shares having fallen more than 20% since their February high point. The firm highlights the upcoming July H1 trading update as a potential buying opportunity ahead of Diaceutics’ anticipated return to earnings profitability this year. RBC forecasts H1 revenue of £15.9m, representing 32% year-over-year growth at constant exchange rates, with the company having already reported £8.4m revenue (up 35% year-over-year) for the four months to April. For the full year, the firm projects 26% constant currency revenue growth to £39.5m with an adjusted EBITDA margin of 17.8%. The analysts were encouraged by Diaceutics’ commercial momentum, demonstrated by a 93% year-over-year increase in Total Contract Value to £18.7m in the four months to April. However, they look for improvement in the multi-year order book, which declined at the end of 2024 despite strong one-year visibility. On a mid-term basis, RBC calculates more than three times potential upside to the current valuation, based on expectations for sustainable margins in the high-20% to 30% range, and up to six times upside in a potential merger and acquisition scenario. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Before you buy stock in DXRX, consider this: ProPicks AI are 6 easy-to-follow model portfolios created by Investing.com for building wealth by identifying winning stocks and letting them run. Over 150,000 paying members trust ProPicks to find new stocks to buy – driven by AI. The ProPicks AI algorithm has just identified the best stocks for investors to buy now. The stocks that made the cut could produce enormous returns in the coming years. Is DXRX one of them?

Click Subscribe #Diaceutics #StockMarket #Investing #FinancialNews #StockPrice

Click Subscribe #Diaceutics #StockMarket #Investing #FinanceNews #OrganicGrowth

DXRX- The Diagnostic Network Access the latest IVDR report from DXRX- The Diagnostic Network

Platomics is collaborating with #Diaceutics to double up on our shared goal of providing labs with resources and solutions to facilitate bringing precision medicine diagnostics to patients faster. ( @dxrx-labnetwork.bsky.social )

Access the report: